Short-term therapeutic effect and safety of endostar combined with XELIRI regimen in the treatment of advanced colorectal cancer / 南方医科大学学报
Journal of Southern Medical University
;
(12): 813-814, 2010.
Article
in Chinese
| WPRIM
| ID: wpr-355013
ABSTRACT
<p><b>OBJECTIVE</b>To evaluate the short-term efficacy and toxicity of endostar in combination with XELIRI as the second-line treatment for advanced colorectal cancer.</p><p><b>METHODS</b>Twenty-one patients with advanced colorectal cancer were treated with intravenous infusion of endostar (15 mg/day for 14 consecutive days) and irinotecan (250 mg/m(2), single dose on the first day), and oral administration of capecitabine (1.0 mg/m(2), twice daily for 14 days), and the treatment cycle was repeated every 21 days. The efficacy and toxicity of the treatments were evaluated according to RECIST and NCI-CTCAE3.0 standard, respectively.</p><p><b>RESULTS</b>The overall response rate was 9.5% in these patients, with a median time to progression (mTTP) of 3.9 months. The main adverse effects associated with the treatment included leucopenia, nausea/vomiting and peripheral neuritis.</p><p><b>CONCLUSION</b>Endostar combined with XELIRI is effective and safe as the second-line treatment for advanced colorectal cancer, and further clinical investigation is warranted.</p>
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Recombinant Proteins
/
Camptothecin
/
Colorectal Neoplasms
/
Antineoplastic Combined Chemotherapy Protocols
/
Endostatins
/
Therapeutic Uses
/
Deoxycytidine
/
Drug Therapy
/
Capecitabine
/
Fluorouracil
Limits:
Adult
/
Aged
/
Female
/
Humans
/
Male
Language:
Chinese
Journal:
Journal of Southern Medical University
Year:
2010
Type:
Article
Similar
MEDLINE
...
LILACS
LIS